Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Ovid Therapeutics Inc.

< Previous 1 2 Next >
News headline image
Ovid Therapeutics and Graviton Bioscience Announce Topline Data from a Phase 1 Clinical Trial Studying OV888/GV101 Capsule, a Potential First-In-Class Therapy for Cerebral Cavernous Malformations
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers LGND OVID
News headline image
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 2nd Annual Needham Virtual Neuroscience Forum
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Studies Published in Cell Reports Medicine Validate the Potential of Direct KCC2 Activation in Resistant Seizures
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present at the 43rd Annual Cowen Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
News headline image
Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Tickers OVID
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.